Ver­sant pulls the wraps off of near­ly $1B in 3 new funds out to build the next fleet of biotech star­tups. And this new gen­er­a­tion is built for speed

Brad Bol­zon has an apol­o­gy to of­fer by way of in­tro­duc­ing a set of 3 new funds that to­geth­er pack a $950 mil­lion wal­lop in new biotech cre­ation and growth.

“I want to apol­o­gize,” says the Ver­sant chair­man and man­ag­ing part­ner, laugh­ing a lit­tle in the in­tro, “that we don’t have any­thing fan­cy or flashy to tell you about our new fund. Same team, around the same amount of cap­i­tal, same in­vest­ment strat­e­gy. If it ain’t broke, don’t fix it.”

But then there’s the flip side, where every­thing has changed. Or at least speed­ed in­to a rel­a­tive blur. Here’s Bol­zon:

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER